Strategic roadmap
In the current context, this does not amount to a rigid list of product milestones: it is a framework of priorities, industrial options and adaptability.

Distributed diagnostics
Decentralisation of molecular testing to nodes close to where the need arises, provided that quality, traceability and network governance remain under control.[3][5] 

Multiplexing
Increasing the information density of the test in contexts where speed must be accompanied by greater decision-making content, not merely a proliferation of targets.[4]

Diagnostic data layer
A software layer capable of supporting execution, data collection, audit trails, quality control and workflow integration; in more mature architectures, it tends to be a structural part of the product.[8][9][10][16] 

Tiered architecture
qPCR, PCR panels and NGS do not cancel each other out: they meet different needs along the same molecular pathway.[2][11]

Platform logic
Value shifts from the individual component to the ability to make reagents, hardware, software, quality, application support and data work together.[2][3][5]

Any strategic insight into the future of molecular diagnostics should begin with a clarification: in a sector such as this, a rigid five-year roadmap risks becoming outdated before it is even implemented. The reason is not a general sense of uncertainty, but the very nature of the sector itself. Regulation, software, AI, documentation standards, access to tests and the convergence of different technologies are all evolving in tandem. [1][2][6][7][8][9][10]

The World Health Organisation itself treats the strengthening of diagnostic capacity as a systemic issue, not as a technical detail of the laboratory.[1] The most recent reviews also show that the focus is shifting from the individual assay to the platform and from the isolated test to the governed workflow. [2] For this reason, rather than asking what linear roadmap Helyx will follow over the next five years, it is more useful to ask which industry trends are currently robust enough to guide credible industrial decisions — and in what respects the group’s architecture is consistent with them.

A traditional roadmap works well when the value chain is relatively stable: development, validation, launch, growth. In molecular diagnostics, the reality is less linear. A product no longer depends solely on its analytical performance; it must coexist with software, cybersecurity, documentation requirements, post-market surveillance, data management and interoperability.[2][6][7][8][9][10]

The IVDR has made it clear that, for IVD products, the robustness of the quality system, technical documentation and performance evaluation carry as much weight as the technological promise.[6][10]

The AI Act and the latest MDCG guidance add a further level of maturity: when software incorporates automation or AI functions, the key question is no longer simply ‘does it work?’, but also ‘how is it qualified?’, ‘how is it classified?’ and ‘how does it integrate with the vertical IVD framework?’.[7][8] [9]

This shifts the strategic value from the idea of a fixed plan to the ability to build a portfolio of coherent options, with clear and adaptable industrial scopes.

The first trend set to endure is not a specific technology, but an architectural principle: diagnostic capability tends to become distributed. The point is no longer simply to take testing out of the central laboratory, but to do so in a way that is quality-assured, traceable and integrated. In other words, decentralisation matters when it is designed as a network, not as an isolated demonstration of portability.[3] [5]

The most recent literature on molecular point-of-care testing emphasises precisely this: decentralised models generate value when training, governance, quality control and lines of accountability are designed for real-world contexts.[3] Studies on sample-to-result platforms also show that ease of use, workflow robustness, sample management and transferability across different contexts are factors just as important as analytical sensitivity alone. [5] In the coming years, the value will therefore not lie in ‘testing anywhere’, but in doing so where it is truly needed, within a manageable system.

The second key aspect concerns the information density of the test. In various clinical pathways, the advantage is no longer merely to produce a result quickly, but to condense the most decision-relevant information into a short timeframe. Here, multiplexing and deep multiplexing become valuable not as a race to target the highest number of targets, but as a means of increasing the test’s decision-relevant content in selected contexts. [4]

Reviews of rapid multiplex molecular syndromic panels show that these tools can support the decision-making process, particularly when used in the right contexts — for example, infectious syndromes with high diagnostic ambiguity or settings where the timing of the decision is particularly critical. [4] The correct message, however, must remain clear: there is no uniform clinical benefit for every panel and every laboratory. The value of multiplexing depends on the context of use, the interpretability of the result, the quality of the reagents and its integration into the actual workflow.

In modern molecular diagnostics, the product is increasingly less likely to be defined solely by the reagent or the instrument alone. What matters more and more is the entire system that links test execution, data collection, audit trails, quality control, workflow management and support for interpretation within defined limits of use.[2][8][9][10]

This is even more true when analytical capacity is distributed across multiple sites and operators. In this scenario, software, the cloud and automation are not mere accessories: they become components of operational consistency. From a regulatory perspective, however, this requires caution in communication. The IVDR, AI Act and MDCG guidance call for a more nuanced understanding of the relationship between software, risk, intended use, classification and liability.[6][7][8][9] [10]

For Helyx, this approach is particularly evident within the Hyris framework. Hyris System™ and the bAPP™ layer reveal a platform logic in which the device, software and data management all fall within the same industrial framework. [13][16] Here too, however, the language must remain precise: the most defensible approach is not to suggest a replacement for clinical expertise, but to describe an infrastructure capable of supporting workflows, traceability, process control and assisted interpretation within defined contexts and uses.

One of the most misleading oversimplifications is to view the future of diagnostics as an ideological shift: qPCR today, NGS tomorrow. The most robust reviews tell a different story. On the one hand, nucleic acid testing remains the cornerstone of modern molecular diagnostics; on the other, the expansion of NGS in the clinical setting broadens the scope of what can be expected from the data, particularly when panel customisation, greater genomic coverage or more sophisticated bioinformatics pipelines are required. [2][11] The point is therefore not to choose a single ‘winner’, but to design tiered architectures. qPCR often remains the preferred choice when speed, operational simplicity, portability and highly standardised workflows are required. Multiplexing increases information density when the laboratory needs more decision-making content without sacrificing established processes. NGS comes into play when the question requires genomic breadth, panel customisation or bioinformatics pipelines that go beyond the scope of a single assay.[2][4][11]

In this context, the Helyx three-division architecture takes on industrial coherence: Hyris oversees distributed qPCR; Vytro covers the clinical IVD PCR sector and deep multiplexing; Mytho covers custom NGS and advanced bioinformatics pipelines.[12][13][14][15] These are not three parallel paths that ignore one another, but three levels of response to different needs, provided that their language, targets and degree of maturity are not confused.

The fifth key area concerns the way in which the market purchases, adopts and uses diagnostics. Increasingly, value is not perceived in the individual kit or isolated device, but in the ability to provide a system that reduces friction: faster onboarding, integration with existing tools, distributed control, application support, OEM services and consistent data flow management.[2][3] [5]

This shift is already evident in the decentralised programmes described in the literature: analytical performance matters, but it is not enough on its own. Training, network governance, distributed quality, interoperability and the ability to adapt the system to specific contexts are required. [3][5] It is here that the platform becomes an industrial logic, not a commercial label. It also becomes clearer why, in the coming years, value will tend to be concentrated in those capable of bringing together technology, quality and implementation.

Viewed through these five key areas, the Helyx architecture appears consistent with the group’s new structure. This consistency, however, should be described as a structural alignment rather than as an advantage already proven by the market. This is an important distinction, particularly in an insight article aimed at partners, investors and regulatory stakeholders.

Hyris is the division most directly aligned with the theme of distributed qPCR and the integrated platform, with Hyris System™, distributed solutions, agrifood & nutraceuticals and OEM services.[13][16]

Vytro represents the PCR IVD and deep multiplexing segment aimed at hospitals and laboratories, that is, the point where laboratory quality, information density and clinical intended use become central. [14]

Mytho covers the custom NGS side, with customised panels, advanced sequencing solutions and bioinformatics pipelines configured to address specific laboratory or research questions.[15]

This is its most defensible role today: bespoke NGS coverage and advanced bioinformatics, not a narrative shortcut towards an entire, already industrialised end-to-end clinical interpretation platform. This three-way division does not in itself demonstrate an acquired competitive advantage, but it makes the group’s industrial structure clearer. In a context where the market increasingly rewards clarity of scope, quality of documentation and integration capabilities, this clarity is already a reputational and strategic asset.[12][13][14][15]

First sign:
the ability to demonstrate that decentralised models remain reliable even outside the central laboratory, with convincing quality, traceability and network governance.[3][5]

Second sign:
the adoption of multiplexing in contexts where the clinical and operational benefit is genuinely measurable, not merely claimed. [4]

Third sign:
the way in which software and AI will be made compatible with the IVDR, the AI Act and a robust approach to process auditability.[6][7][8][9][10]

Fourth sign:
the evolution of tiered models, in which qPCR, PCR panels and NGS coexist not as ideological alternatives but as different levels of diagnostic response.[2][11]

Fifth sign:
the demand for partners capable of providing not only products, but systems that are integrable, customisable and industrially sustainable over time.[2][3][5]

The future of molecular diagnostics cannot be accurately predicted through a rigid, linear roadmap that is entirely laid bare to the public. It will be a future shaped by convergences: between decentralisation and governance, between PCR and NGS, between analytical performance and workflow quality, and between software innovation and regulatory responsibility.[2][6][7][8][11] For this reason, the strategic value lies not in promising every single move in advance, but in demonstrating an architecture coherent enough to adapt to changes without losing direction. Viewed in this light, Helyx has more to gain by showing precisely how Hyris, Vytro and Mytho occupy distinct yet complementary segments of the molecular market, each with a consistent language, target audience and level of maturity. [12][13][14][15] Beyond the roadmap, therefore, there is a more useful question: which industrial structures will be robust enough to remain relevant as the sector changes? In molecular diagnostics today, credibility lies with those who know how to be precise before being expansive. It is in this space that Helyx can strengthen a serious, clear and reputationally more solid industrial positioning.